New combo aims to make pancreatic cancer surgery safer and more effective

NCT ID NCT06094140

Ongoing Disease control Sponsor: Australasian Gastro-Intestinal Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (mFOLFIRINOX) before surgery is safe and tolerable for people with pancreatic cancer that can be removed. About 20 adults with resectable or borderline resectable pancreatic cancer will receive the combination treatment. The main goal is to see if most patients can complete at least 80% of the planned treatment without serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

GenesisCare North Shore

Sydney, New South Wales, 2065, Australia
Warringal Private Hospital

Melbourne, Victoria, 3084, Australia
Wollongong Hospital

Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.